Alkermes plc reported second quarter 2026 total revenues of $496.0 million, a 27% increase from the prior year period, driven by strong proprietary product sales. GAAP net income was $0.5 million, while Adjusted EBITDA reached $139.2 million. The company announced that Blair Jackson will assume the role of Chief Executive Officer on August 1, 2026, succeeding Chairman Richard Pops, who will remain on the Board. Financial expectations for the full year 2026 were updated, with the GAAP net loss guidance widened to ($95)–($115) million from the previous ($70)–($90) million range, primarily due to a $26.4 million increase in the fair value of contingent consideration related to the Avadel acquisition. Alkermes operates in the biopharmaceutical industry, developing and commercializing innovative medicines in neuroscience.
